Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Tuesday 6th February 2018 from 11.00am to 11.15am (GMT).

During this time our website performance may be temporarily affected. If you have any questions please use the feedback button available under our menu button. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 3, 2018
Previous Article Next Article

Targeted photodynamic therapy in visible light using BODIPY-appended copper(II) complexes of a vitamin B6 Schiff base

Author affiliations


Copper(II) complexes [Cu(L1/L2/L3)(A)] (1–3), where H2A·HCl is a vitamin B6 Schiff base, viz. 3-hydroxy-5-(hydroxymethyl)-4-(((2-hydroxyphenyl)imino)methyl)-2-methylpyridin-1-ium chloride, L1 and L2 are 2-(2-pyridyl)benzimidazole based borondipyrromethene (BODIPY) ligands and L3 is 2-(2-pyridyl)benzimidazole, were prepared, characterized and their visible light-induced anti-cancer activity was studied. Complex 3, characterized by X-ray crystallography, exhibits a distorted square-pyramidal geometry for copper (τ = 0.33). Complexes 1 and 2 showed absorption bands at 500 and 535 nm, respectively, in 20% DMSO/Dulbecco's phosphate buffered saline (DPBS) medium. Complex 1 exhibited emission at ∼510 nm (λexc = 480 nm) (ΦF = 0.1) in 20% DMSO/DPBS, while the non-emissive diiodo-BODIPY complex 2 is an efficient photosensitizer. The green fluorescent complex 1 enabled us to study its cellular uptake and localization. It showed selective uptake in proliferating cancer cells and significant mitochondrial localization (Pearson's coefficient = 0.7). Complex 2 showed excellent photocytotoxicity (400–700 nm, 10 J cm−2) in HeLa, MCF-7 and HepG2 cancer cells with IC50 values within 0.4–0.6 μM, while remaining less toxic in the dark and in non-cancerous HPL1D cells (photocytotoxic index ∼50). Complex 2, remarkable in targeting cancer cells over non-cancerous cells, showed photoinduced generation of singlet oxygen, causing apoptotic cell death, thus satisfying the major requirements of targeted photodynamic therapy.

Graphical abstract: Targeted photodynamic therapy in visible light using BODIPY-appended copper(ii) complexes of a vitamin B6 Schiff base

Back to tab navigation

Supplementary files

Publication details

The article was received on 23 Oct 2017, accepted on 03 Dec 2017 and first published on 04 Dec 2017

Article type: Paper
DOI: 10.1039/C7DT03976J
Citation: Dalton Trans., 2018,47, 823-835
  •   Request permissions

    Targeted photodynamic therapy in visible light using BODIPY-appended copper(II) complexes of a vitamin B6 Schiff base

    N. Mukherjee, S. Podder, K. Mitra, S. Majumdar, D. Nandi and A. R. Chakravarty, Dalton Trans., 2018, 47, 823
    DOI: 10.1039/C7DT03976J

Search articles by author